Cipemastat (also known as Ro32-3555), an inhibitor of MMP1, MMP3 and MMP9 used for the therapy of RA and OA, failed to show any reduction in the process of joint damage in patients with RA in a clinical trial (Milner and Cawston, 2005). Here, MMP3 is linked to rheumatoid arthritis.